Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Oliver McCammon
LIFE
Oliver McCammon
LifeSci Capital
Wall Street Analyst
★★★☆☆
#1730
on 13Foresight · ranked by our own returns
14%
Success Rate
-7.2%
Average Return
1 of 7 calls profitable · -7.3% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 14% of Oliver McCammon's ratings turned a profit when each position was held for 1 year — averaging -7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

58 Buy 0 Hold 0 Sell
Oliver's Stock Coverage 8 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CELC
Celcuity
 Jun 02, 2026 BUY Strong Buy
+40.6% avg upside
16 analysts
$165.00
87.93% Upside
 -3.7%
CRBP
Corbus Pharmaceuticals
 May 26, 2026 BUY Strong Buy
+338.6% avg upside
20 analysts
$38.00
360.09% Upside
 ·
CADL
Candel Therapeutics
 May 16, 2026 BUY Strong Buy
+112.6% avg upside
10 analysts
$16.00
92.47% Upside
 +10.4%
INBX
Inhibrx Biosciences Inc
 May 16, 2026 BUY Strong Buy
+198.3% avg upside
5 analysts
$230.00
147.22% Upside
 -12.8%
AURA
Aura Biosciences Inc
 May 16, 2026 BUY Strong Buy
+234.5% avg upside
9 analysts
$23.00
262.81% Upside
 -14.2%
CATX
Perspective Therapeutics
 May 16, 2026 BUY Strong Buy
+278.9% avg upside
22 analysts
$15.00
408.42% Upside
 -22.1%
JANX
Janux Therapeutics Inc
 May 09, 2026 BUY Strong Buy
+217.9% avg upside
21 analysts
$60.00
321.92% Upside
 -0.6%
GLUE
Monte Rosa Therapeutics
 May 07, 2026 BUY Strong Buy
+27.3% avg upside
14 analysts
 — -7.6%
🔒 3 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Oliver McCammon — Frequently Asked Questions
How accurate are Oliver McCammon's stock ratings?
Based on the calls 13Foresight could measure, about 14% of Oliver's ratings were profitable over a one-year hold, with an average return of -7.2% per rating, or -7.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Oliver ranked on 13Foresight?
Oliver McCammon is currently ranked #1730 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Oliver cover?
Oliver most recently has ratings on CELC, CRBP, CADL, INBX, AURA, CATX, JANX, GLUE. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.